Maria Rojek-Lucas Company News
Proteon Pharmaceuticals COO Matthew Tebeau sat down with Christine Corrado from Proactive Investors at the 11th Annual BioTech Showcase in San Francisco. The Poland-based biotech aims to reduce reliance on antibiotics by using naturally-occurring bacteriophages to prevent and treat infectious diseases.
Cases of salmonellosis are a growing problem – their number has been steadily growing for the last two years exceeding the number of 10 thousand cases per year. One of the main sources of infection are eggs and poultry. Few months ago new set of rules was implemented regarding national program for the control of […]
Proteon Pharmaceuticals was an invited speaker at the 9th edition of the FIAAP Animal Nutrition conference held on March 27, 2018 in Bangkok, Thailand. This one-day international conference highlighted the latest innovations and research in animal feed ingredients and additives. The event was co-located with five additional conferences as part of VICTAM Asia 2018. (more…)
October 24, 2017 – Proteon Pharmaceuticals S.A., a Polish biotechnology firm has signed an agreement with an international Investment Fund, the Aqua-Spark fund, which invests in sustainable aquaculture. Proteon Pharmaceuticals will use the funds to commercialize its products globally, develop production capacity and support the development of its bacteriophage-platform technology. Proteon Pharmaceuticals is a world […]
Proteon Pharmaceuticals presents its unique product BAFADOR® at the international bacteriophage conference in Tbilisi Proteon Pharmaceuticals participated in the international conference “Centennial Celebration of Bacteriophage Research”, held in Tbilisi, Georgia on June 26-29, 2017. Proteon Pharmaceuticals’ R&D Director, Dr Ewelina Wójcik, presented the results of Company’s research, which has led to development of a phage-based […]
In 2016 Proteon Pharmaceuticals awarded grants from Polish Center for Research & Development for Euro 3.2 m In 2016, Proteon Pharmaceuticals signed the agreements for the co-financing five research projects from the European Union for Euro 3.2 million. The projects are for research and development of new generation, innovative products, based on our unique phage-platform […]
